Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A

Immunology Letters

Volumn 111, Issue 1, 2007, Pages 26-35

  Gartner, Tatiana ^a,b,c   Baeten, Martijn ^b,c   Otieno, Samuel ^b,c   Revets, Hilde ^b,c   De Baetselier, Patrick ^b,c   Huygen, Kris ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Ag85A; OprI; Tuberculosis

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LIPOPROTEIN; MYCOLYL TRANSFERASE ANTIGEN 85A; PLASMID DNA; PROTEIN OPRI; PROTEIN OPRI AG85A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CERVICAL LYMPH NODE; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; MEDIASTINUM LYMPH NODE; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TH1 CELL; TUBERCULOSIS; VACCINATION;

ACYLTRANSFERASES; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; IMMUNIZATION, SECONDARY; INTERLEUKIN-10; INTERLEUKIN-4; LIPOPROTEINS; MICE; PSEUDOMONAS AERUGINOSA; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTORS; TUBERCULOSIS; VACCINES, DNA;

EID: 34347335556     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.04.010     Document Type: Article

References (46)

1. WHO. http://www.who.int/mediacentre/factsheets/fs104/en; 2004.
2. Tiruviluamala P., Reichman L.B., and Tuberculosis. Annu Rev Public Health 23 (2002) 403-426
3. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
4. Kaufmann S.H. Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 6 (2006) 699-704
5. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., and Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171 (2003) 1602-1609
6. Chen L., Wang J., Zganiacz A., and Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 72 (2004) 238-246
7. Santosuosso M., Zhang X., McCormick S., Wang J., Hitt M., and Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 174 (2005) 7986-7994
8. Swain S.L. Regulation of the generation and maintenance of T-cell memory: a direct, default pathway from effectors to memory cells. Microbes Infect 5 (2003) 213-219
9. Kipnis A., Irwin S., Izzo A.A., Basaraba R.J., and Orme I.M. Memory T lymphocytes generated by Mycobacterium bovis BCG vaccination reside within a CD4 CD44lo CD62 Ligandhi population. Infect Immun 73 (2005) 7759-7764
10. Wu C.Y., Kirman J.R., Rotte M.J., Davey D.F., Perfetto S.P., Rhee E.G., et al. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 3 (2002) 852-858
11. Romano M., D'Souza S., Adnet P.Y., Laali R., Jurion F., Palfliet K., et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24 (2006) 3353-3364
12. Revets H., Pynaert G., Grooten J., and De Baetselier P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 174 (2005) 1097-1103
13. Cote-Sierra J., Bredan A., Toldos C.M., Stijlemans B., Brys L., Cornelis P., et al. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major. Infect Immun 70 (2002) 240-248
14. Rau H., Revets H., Cornelis P., Titzmann A., Ruggli N., McCullough K.C., et al. Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever. Vaccine 24 (2006) 4757-4768
15. Ronning D.R., Klabunde T., Besra G.S., Vissa V.D., Belisle J.T., and Sacchettini J.C. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat Struct Biol 7 (2000) 141-146
16. Wiker H.G., and Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56 (1992) 648-661
17. Baldwin S.L., D'Souza C., Roberts A.D., Kelly B.P., Frank A.A., Lui M.A., et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66 (1998) 2951-2959
18. Feng C.G., Palendira U., Demangel C., Spratt J.M., Malin A.S., and Britton W.J. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect Immun 69 (2001) 4174-4176
19. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 (1996) 893-898
20. Doherty T.M., Olsen A.W., Weischenfeldt J., Huygen K., D'Souza S., Kondratieva T.K., et al. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis 190 (2004) 2146-2153
21. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
22. Santosuosso M., McCormick S., Zhang X., Zganiacz A., and Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74 (2006) 4634-4643
23. Brooks J.V., Frank A.A., Keen M.A., Bellisle J.T., and Orme I.M. Boosting vaccine for tuberculosis. Infect Immun 69 (2001) 2714-2717
24. Tanghe A., D'Souza S., Rosseels V., Denis O., Ottenhoff T.H., Dalemans W., et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 69 (2001) 3041-3047
25. Cote-Sierra J., Jongert E., Bredan A., Gautam D.C., Parkhouse M., Cornelis P., et al. A new membrane-bound OprI lipoprotein expression vector. High production of heterologous fusion proteins in Gram (-) bacteria and the implications for oral vaccination. Gene 221 (1998) 25-34
26. Cornelis P., Sierra J.C., Lim Jr. A., Malur A., Tungpradabkul S., Tazka H., et al. Development of new cloning vectors for the production of immunogenic outer membrane fusion proteins in Escherichia coli. Biotechnology (NY) 14 (1996) 203-208
27. Cornelis P., Bouia A., Belarbi A., Guyonvarch A., Kammerer B., Hannaert V., et al. Cloning and analysis of the gene for the major outer membrane lipoprotein from Pseudomonas aeruginosa. Mol Microbiol 3 (1989) 421-428
28. Denis O., Tanghe A., Palfliet K., Jurion F., van den Berg T.P., Vanonckelen A., et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 66 (1998) 1527-1533
29. De Bruyn J., Huygen K., Bosmans R., Fauville M., Lippens R., Van Vooren J.P., et al. Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. Microb Pathog 2 (1987) 351-366
30. Huygen K., Abramowicz D., Vandenbussche P., Jacobs F., De Bruyn J., Kentos A., et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun 60 (1992) 2880-2886
31. D'Souza S., Rosseels V., Romano M., Tanghe A., Denis O., Jurion F., et al. Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect Immun 71 (2003) 483-493
32. Huygen K., Lozes E., Gilles B., Drowart A., Palfliet K., Jurion F., et al. Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG. Infect Immun 62 (1994) 363-370
33. Tanghe A., Lefevre P., Denis O., D'Souza S., Braibant M., Lozes E., et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 162 (1999) 1113-1119
34. Borsutzky S., Kretschmer K., Becker P.D., Muhlradt P.F., Kirschning C.J., Weiss S., et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 174 (2005) 6308-6313
35. Hayashi E.A., Akira S., and Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol 174 (2005) 6639-6647
36. Giri P.K., Verma I., and Khuller G.K. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J Infect (2006)
37. Abolhassani M., Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Infect Immun 68 (2000) 5657-5662
38. Lagranderie M., Chavarot P., Balazuc A.M., and Marchal G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 18 (2000) 1186-1195
39. Tree J.A., Williams A., Clark S., Hall G., Marsh P.D., and Ivanyi J. Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin Exp Immunol 138 (2004) 405-409
40. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173 (2004) 6357-6365
41. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 (2004) 6622-6632
42. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., and Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177 (2006) 6353-6360
43. Andersen C.S., Dietrich J., Agger E.M., Lycke N.Y., Lovgren K., and Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior BCG immunity to Mycobacterium tuberculosis. Infect Immun (2006)
44. Casanova J.L., and Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20 (2002) 581-620
45. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 (1993) 2243-2247
46. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 (2005) 1804-1813